San Diego-based Engrail Therapeutics, a neurological in-licensing company, has acquired Neurocycle Therapeutics, a firm that specializes in sub-type selective GABA-A modulation.
"Our flexible transaction model and science-first approach allows us to acquire high-quality assets with a lower-risk path to market where significant patient need still exists," said Vikram Sudarsan, president and CEO at Engrail Therapeutics. "We combine a comprehensive view of clinical development strategy, regulatory considerations and intellectual property to find differentiated assets with validated mechanisms of action. GABA-A is a well validated target and modulators of this receptor have therapeutic effect across a broad range of neurological and psychiatric conditions. We now have multiple sub-type selective GABA-A modulators with strong profiles and look forward to rapidly advancing development."
With financial support from Nan Fung Life Sciences, Engrail will to continue to combine a comprehensive view of clinical development strategy, regulatory considerations and intellectual property to find differentiated assets with validated mechanisms of action, ultimately catalyzing a diverse portfolio of therapies to treat diseases of the nervous system.
Founded in 2019, Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. The company plans to initiate clinical trials with multiple assets in 2021.